- Open Access
Successful adoptive transfer and in vivo expansion of haploidentical γδ T cells
© Wilhelm et al.; licensee BioMed Central Ltd. 2014
Received: 12 November 2013
Accepted: 30 January 2014
Published: 15 February 2014
The primary aim of this pilot study was to determine the feasibility and safety of an adoptive transfer and in vivo expansion of human haploidentical γδ T lymphocytes.
Patients with advanced haematological malignancies who are not eligible for allogeneic transplantation received peripheral blood mononuclear cells from half-matched family donors. For that, a single unstimulated leukapheresis product was incubated with both the anti-CD4 and anti-CD8 antibodies conjugated to paramagnetic particles. The depletion procedure was performed on a fully automated CliniMACS® device according to the manufacturer’s instructions. On average, patients received 2.17 × 106/kg (range 0.9-3.48) γδ T cells with <1% CD4- or CD8-positive cells remaining in the product. All patients received prior lymphopenia-inducing chemotherapy (fludarabine 20-25 mg/m2 day -6 until day -2 and cyclophosphamide 30-60 mg/kg day -6 and -5) and were treated with 4 mg zoledronate on day 0 and 1.0x106 IU/m2 IL-2 on day +1 until day +6 for the induction of γδ T cell proliferation in vivo.
This resulted in a marked in vivo expansion of donor γδ T cells and, to a lower extent, natural killer cells and double-negative αβ T cells (mean 68-fold, eight-fold, and eight-fold, respectively). Proliferation peaked by around day +8 and donor cells persisted up to 28 days. Although refractory to all prior therapies, three out of four patients achieved a complete remission, which lasted for 8 months in a patient with plasma cell leukaemia. One patient died from an infection 6 weeks after treatment.
This pilot study shows that adoptive transfer and in vivo expansion of haploidentical γδ T lymphocytes is feasible and suggests a potential role of these cells in the treatment of haematological diseases.
For many patients with refractory haematological malignancies, allogeneic stem cell transplantation (SCT) remains the only chance of a cure. However, due to its high toxicity, a significant number of patients are not eligible for this approach.
The anti-tumour activity of allogeneic SCT is primarily mediated by an immunological graft-versus-tumour effect mediated by donor lymphocytes. Ruggeri et al. demonstrated that a KIR ligand mismatch enhanced the donor natural killer (NK) cell alloreactivity in haploidentical transplantations, through a “missing self-recognition” in patients with AML. Furthermore, Miller et al. described a successful adoptive transfer and in vivo expansion of haploidentical NK cells by interleukin 2 (IL-2) in a non-transplantation setting. The major advantages of immunotherapy with innate lymphocytes compared with MHC-restricted αβ T cells are that they can kill tumour cells without prior exposure and do not induce graft-versus-host disease (GVHD).
Human γδ T cells not only recognise microbial antigens, but are also capable of exerting significant MHC-unrestricted activity against a broad spectrum of tumour cells in vitro, especially haematological neoplasia[6, 7]. Although their mechanism of target cell recognition is not fully understood, it is known that Vγ9Vδ2 T cells, which represent the vast majority of human circulating γδ T cells, recognise naturally occurring and synthetic phosphoantigens (i.e., aminobisphosphonates such as pamidronate or zoledronate)[8, 9].
In two previous trials (phase I/II) in patients with relapsed/refractory malignancies, we demonstrated that a combination of pamidronate or zoledronate and low-dose IL-2 not only induced the selective activation and proliferation of Vγ9Vδ2 T cells in vivo, but could also be accompanied by anti-tumour activity[10, 11]. However, a general drawback of autologous γδ T cell-mediated tumour-immunotherapy is the frequent impaired function of γδ T cells in up to 50-70% of cancer patients[7, 10, 12].
Here, we present for the first time data showing that the adoptive transfer of haploidentical γδ T cells is a feasible and safe method for the in vivo expansion of these innate immune effector cells in patients with refractory haematological malignancies.
Methods and materials
Patients and treatment protocol
In this pilot study, four subsequent patients with advanced refractory haematological malignancies (one T-NHL, one AML, one secondary plasma cell leukaemia, and one multiple myeloma) who were not eligible for allogeneic transplantation were included. HLA typing of the patients and their haploidentical family members were performed to select a donor with an HLA mismatch, which was detectable by FACS analysis with an HLA-specific antibody. Infusion of a CD4/CD8 T cell-depleted leukapheresis product (donor innate lymphocyte infusion = DILI) and Hi-Cy/Flu as prior immunosuppressive chemotherapy (fludarabine 25 mg/m2 day -6 until day -2 and cyclophosphamide 60 mg/kg day -6 and -5) were performed as described[2, 4, 5]. However, according to the general conditions and/or prior therapies, the dose of cyclophosphamide was reduced by 50% in patients 1 and 2, and both cyclophosphamide/fludarabine by 25% in patients 3 and 4. All patients received intravenous (i.v.) zoledronate at a dose of 4 mg after DILI infusion on day 0 and subcutaneous (s.c.) 1.0x106 IU/m2 IL-2 on day +1 until day +6.
The collection of PBMCs and depletion of CD4+ and CD8+ cells were performed as previously described. In brief, a single unstimulated leukapheresis was performed from family donors using a Cobe Spectra (Gambro BCT, Planegg-Martinsried, Germany). The cells were incubated with anti-CD4 and anti-CD8 antibodies conjugated to paramagnetic particles and then processed with the fully automated device CliniMACS® Plus (Miltenyi Biotec) using the program “Depletion 2.1”, according to the manufacturer’s instructions.
This pilot study was approved by the institutional review board and all participants gave written informed consent.
Flow cytometric analysis
Leukapheresis products and patient samples were analysed using CD3, CD4, CD8, CD14, CD15, CD16 + CD56, CD19, TCRαβ, and TCRγδ fluorochrome-labelled antibodies by four-colour FACS analysis (Epics XL/FC500, Beckman Coulter). In vivo expansion of HLA-mismatched donor lymphocytes was followed by FACS-based chimerism analysis with prior tested specific antibodies every other day.
Results and discussion
Patient characteristics and cell products
No. prior regimens
Cell dose (10 6 /kg)
γδ T cells
αβ T cells
CD4+ T cells
CD8+ T cells
Engraftment and expansion of donor cells
Our prior trials in the autologous setting clearly showed that the expansion of γδ T cells in vivo was a prerequisite for tumour regression, since only patients with significant in vivo proliferation of γδ T cells exhibited a tumour response. Therefore, one major goal of our study was to investigate the feasibility and tolerability of selective in vivo expansion of the adoptively transferred haploidentical γδ T cells. For that, patients received a phosphoantigen (4 mg zoledronate) and low-dose IL-2 (1-2 × 106 IE) s.c. for 6 days, starting on day 1 after transfusion. The results showed that a transient but significant expansion of donor γδ T cells and, to a lower extent, of donor NK cells and DN αβ T cells occurred in these patients (Figure 1). In all patients, proliferation peaked by around day +8, while on day +15, in three out of four patients there were no detectable donor cells, concurrent with the regeneration of recipient cells. The mean number of γδ T cells, NK cells and DN αβ T cells was approximately 43 cells/μL, 9 cells/μL, and 6 cells/μL, which represented a 68-fold, an eight-fold, and an eight-fold expansion, respectively. However, in patient 4, who showed the most profound γδ T cell expansion, cells were detectable for as long as 28 days after transfusion. Due to the underlying disease and multiple prior therapies including autologous stem cell transplantation, patient 4 was severely immunosuppressed, suggesting that the degree of immunosuppression may be a determinant in the duration of engraftment. Miller et al. have already shown that the survival of haploidentical lymphocytes is dependent on the extent of prior immunosuppression by comparing low- and high-intensity regimens.
The duration of neutropenia (< 500/μl) was 20 (range 11-33) days. Although it has not been shown that γδ T cells recognise alloantigens, potential hazardous effects of in vivo stimulated mismatched γδ T cells was of major concern. Although patient 4 died from severe septicaemia (Staphylococcus epidermidis + Enterobacter faecium) on day +45, with his haematopoiesis already recovered, none of the patients showed any signs of acute or chronic GVHD nor organ injury (Table 1).
Three out of four patients achieved a complete remission, which lasted between 2 and 8 months. For example, patient 3, who suffered from secondary plasma cell leukaemia and did not respond to 3 different regimens including autologous stem cell transplantation, also achieved a stringent complete remission (Figure 1).
It cannot be excluded, that the Flu/Cy regimen given prior cell transfusion for lymphopenia induction, induced a significant tumour regression in the patients. However, refractoriness to all other prior treatment approaches and the kind of underlying diseases argues against this assumption. Due to the small patient number, we were not able to differentiate which cell population was the main contributor for remission induction. Figure 1 shows the expansion of NK cells, αβ T cells and γδ T cells. It is very likely that the αβ T cell population consists at least in part of double-negative (classically Va24 + CD3+) invariant natural killer T (iNKT) cells. Given the known efficacy of iNKT cells against lymphoid tumour cells, it is possible that besides αβ T cells and “classical” NK cells, this subpopulation contributed to the anti-tumour effect, particularly in the cases of lymphoid malignancies[14, 17–20].
This pilot study showed for the first time that infusion of haploidentical γδ T cells is feasible and the administration of phosphoantigens and low-dose IL-2 induces a significant proliferation of donor γδ T cells in vivo[10, 11]. In addition, this clinical trial provides the first evidence that selective stimulation of allogeneic γδ T cells can be accompanied by anti-tumour activity in vivo without inducing GVHD.
We thank Elisabeth Holzmann, Rosemarie Ottohal, and Christine Öhrlein for their expert technical assistance. This work was supported by “Verein Hilfe für Krebskranke e.V.”.
- Ruggeri L, Capanni M, Urbani S, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002, 295: 2097-2100. 10.1126/science.1068440.View ArticlePubMedGoogle Scholar
- Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005, 105 (8): 3051-3057. 10.1182/blood-2004-07-2974.View ArticlePubMedGoogle Scholar
- Lowdell MW, Lamb L, Hoyle C, Velardi A, Prentice HG: Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias. Br J Haematol. 2001, 114: 11-24. 10.1046/j.1365-2141.2001.02906.x.View ArticlePubMedGoogle Scholar
- Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W: NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukaemia. J Clin Oncol. 2010, 28: 955-959. 10.1200/JCO.2009.24.4590.PubMed CentralView ArticlePubMedGoogle Scholar
- Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM: Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukaemia patients. Blood. 2011, 118: 3273-3279. 10.1182/blood-2011-01-329508.View ArticlePubMedGoogle Scholar
- Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M: Stimulation of γδ T cells by aminobisphosphonates and induction of anti-plasma cell activity in multiple myeloma. Blood. 2000, 96: 384-392.PubMedGoogle Scholar
- Kunzmann V, Wilhelm M: Anti-Lymphoma effect of γδ T cells. Leukemia Lymphoma. 2005, 46: 671-680. 10.1080/10428190500051893.View ArticlePubMedGoogle Scholar
- Kunzmann V, Bauer E, Wilhelm M: γδ T cell stimulation by pamidronate. N Engl J Med. 1999, 340: 737-738. 10.1056/NEJM199903043400914.View ArticlePubMedGoogle Scholar
- Wang H, Henry O, Distefano MD, Wang YC, Räikkönen J, Mönkkönen J, Tanaka Y, Morita CT: Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol. 2013, 191 (3): 1029-1042. 10.4049/jimmunol.1300658.View ArticlePubMedGoogle Scholar
- Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP: γδ T cells for Immune therapy of patients with lymphoid malignancies. Blood. 2003, 102: 200-206. 10.1182/blood-2002-12-3665.View ArticlePubMedGoogle Scholar
- Kunzmann V, Smetak M, Kimmel B, Weissinger F, Weigang-Koehler K, Birkmann J, Einsele H, Wilhelm M: γδ T cell-mediated immunotherapy of malignancies with zoledronate and IL-2 [abstract]. Blood. 2005, 106 (11): s2439-Google Scholar
- Kunzmann V, Kimmel B, Herrmann T, Einsele H, Wilhelm M: Inhibition of phosphoantigen-mediated γδ T cell proliferation by CD4+CD25+FoxP3+ regulatory T cells (Treg). Immunology. 2009, 126 (2): 256-267. 10.1111/j.1365-2567.2008.02894.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Smetak M, Kimmel B, Birkmann J, Schaefer-Eckart K, Einsele H, Wilhelm M, Kunzmann V: Clinical-scale single-step CD4+ and CD8+ cell depletion for Donor Innate Lymphocyte Infusion (DILI). Bone Marrow Transplant. 2008, 41: 643-650. 10.1038/sj.bmt.1705942.View ArticlePubMedGoogle Scholar
- Young KJ, Kay LS, Phillips MJ, Zhang L: Antitumor activity mediated by double negative T cells. Cancer Res. 2003, 63: 8014-8021.PubMedGoogle Scholar
- Singh B, Read S, Asseman C, Malmström V, Mottet C, Stephens LA, Stepankova R, Tlaskalova H, Powrie F: Control of intestinal inflammation by regulatory T cells. Immunol Rev. 2001, 182: 190-200. 10.1034/j.1600-065X.2001.1820115.x.View ArticlePubMedGoogle Scholar
- Napolitano A, Pittoni P, Beaudoin L, Lehuen A, Voehringer D, MacDonald HR, Dellabona P, Casorati G: Functional education of invariant NKT cells by dendritic cell tuning of SHP-1. J Immunol. 2013, 190: 3299-3308. 10.4049/jimmunol.1203466.View ArticlePubMedGoogle Scholar
- Watarai H, Yamada D, Fujii S, Taniguchi M, Koseki H: Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy. Int J Hematol. 2012, 95: 624-631. 10.1007/s12185-012-1091-0.View ArticlePubMedGoogle Scholar
- Motohashi S, Nakayama T: Invariant natural killer T cell-based immunotherapy for cancer. Immunotherapy. 2009, 1: 73-82. 10.2217/1750743X.1.1.73.View ArticlePubMedGoogle Scholar
- Molling JW, Moreno M, van der Vliet HJ, van den Eertwegh AJ, Scheper RJ, Von Blomberg BM, Bontkes HJ: Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol. 2008, 129: 182-194. 10.1016/j.clim.2008.07.025.View ArticlePubMedGoogle Scholar
- Haraguchi K, Takahashi T, Nakahara F, Matsumoto A, Kurokawa M, Ogawa S, Oda H, Hirai H, Chiba S: CD1d expression level in tumor cells is an important determinant for anti-tumor immunity by natural killer T cells. Leuk Lymphoma. 2006, 47: 2218-2223. 10.1080/10428190600682688.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.